Barbara Mulloy

Title: Barbara Mulloy: Innovator in Medicament Development

Introduction

Barbara Mulloy is a notable inventor based in South Mimms, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic molecules. Her work focuses on modulating the function and activity of interleukin 13, a crucial component in inflammatory responses.

Latest Patents

Barbara holds a patent for the "Selection of medicaments that modulate the function and activity of interleukin 13." This patent involves the design and selection of medicaments in the form of therapeutic molecules, including inflammatory modulators. The target site for these medicaments is interleukin 13 (IL-13), where a glycosaminoglycan (GAG) molecule or polyanionic glycoconjugate modulates IL-13 activity or function. The design targets specific amino acids located in the AB loops and/or helix D of human IL-13 or its homologs. The medicaments developed can be used to modulate various physiological processes, and therapeutic and prophylactic compositions can include these designed medicaments.

Career Highlights

Barbara Mulloy is associated with Glycan Biosciences LLC, where she continues her innovative work in the field of medicinal chemistry. Her research has the potential to impact therapeutic strategies for inflammatory diseases significantly.

Collaborations

Barbara collaborates with Deirdre Roma Coombe, who is also a prominent figure in the field. Their partnership enhances the research and development efforts at Glycan Biosciences LLC.

Conclusion

Barbara Mulloy's contributions to the field of medicinal chemistry through her innovative patent on interleukin 13 modulation exemplify her dedication to advancing therapeutic solutions. Her work continues to pave the way for new treatments in inflammatory conditions.